The annual AACR conference in Chicago will soon highlight groundbreaking advancements, including novel mechanisms, novel modalities and novel combinations, showcasing significant strides in cancer treatment. While not all trials succeed, even setbacks provide critical insights to refine future strategies and improve patient outcomes. We eagerly await next month’s key presentations, which may redefine therapies and drive global collaboration. Every result—whether positive or negative—fuels progress toward our shared goal of defeating cancer.

01,

Abst_ID: CT008
SESSION: ADCs and Immunooncology-focused Biological Approaches
START: 4/27/2025 3:00:00 PM
END: 4/27/2025 3:10:00 PM
PRESENTER: Shun Lu, MD,PhD
TITLE: First-in-human study of SYS6010, a novel EGFR targeting antibody drug conjugate (ADC) for patients with advanced solid tumors
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10395
ABSTRACT: Abstract is embargoed at this time.

02,

Abst_ID: CT009
SESSION: ADCs and Immunooncology-focused Biological Approaches
START: 4/27/2025 3:15:00 PM
END: 4/27/2025 3:25:00 PM
PRESENTER: Shun Lu, PhD
TITLE: SHR-A1811, a HER2-directed antibody-drug conjugate (ADC), in advanced HER2-mutant non-small cell lung cancer (NSCLC): Updated phase 2 results from HORIZON-Lung
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10396
ABSTRACT: Abstract is embargoed at this time.

03,

Abst_ID: CT016
SESSION: New Frontiers in Precision Oncology
START: 4/27/2025 3:30:00 PM
END: 4/27/2025 3:45:00 PM
PRESENTER: Timothy Yap, MD;PhD
TITLE: First-in-human (FIH) phase 1 trial of the oral first-in-class covalent Werner helicase (WRN) inhibitor RO7589831 in patients with microsatellite instable (MSI) and/or mismatch repair deficient (dMMR) advanced solid tumors
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10419
ABSTRACT: Abstract is embargoed at this time.

04,

Abst_ID: CT050
SESSION: Therapeutic Advances in Non-Small Cell Lung Cancer
START: 4/28/2025 10:16:00 AM
END: 4/28/2025 10:31:00 AM
PRESENTER: John Heymach, MD;PhD
TITLE: Zongertinib in patients with pretreated HER2-mutant advanced NSCLC: Beamion LUNG-1
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10423
ABSTRACT: Abstract is embargoed at this time.

05,

Abst_ID: CT051
SESSION: Therapeutic Advances in Non-Small Cell Lung Cancer
START: 4/28/2025 10:46:00 AM
END: 4/28/2025 11:01:00 AM
PRESENTER: Solange Peters, MD;PhD
TITLE: SKYSCRAPER-01: A phase III, randomized trial of tiragolumab (tira) + atezolizumab (atezo) versus placebo (pbo) + atezo in patients (pts) with previously-untreated PD-L1-high, locally advanced unresectable/metastatic NSCLC
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10424
ABSTRACT: Abstract is embargoed at this time.

06,

Abst_ID: CT060
SESSION: First-in-Human Phase I Clinical Trials 1
START: 4/28/2025 2:00:00 PM
END: 4/28/2025 5:00:00 PM
PRESENTER: Weili Zhao, MD
TITLE: First-in-human trial of JMT601, a bispecific fusion protein targeting CD47 and CD20, in patients with relapse/refractory CD20 positive B-cell non-Hodgkin lymphoma
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10436
ABSTRACT: Abstract is embargoed at this time.

07,

Abst_ID: CT063
SESSION: First-in-Human Phase I Clinical Trials 1
START: 4/28/2025 2:00:00 PM
END: 4/28/2025 5:00:00 PM
PRESENTER: Daruka Mahadevan, MD;PhD
TITLE: First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies (NCT04886622)
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10439
ABSTRACT: Abstract is embargoed at this time.

08,

Abst_ID: CT068
SESSION: First-in-Human Phase I Clinical Trials 1
START: 4/28/2025 2:00:00 PM
END: 4/28/2025 5:00:00 PM
PRESENTER: Mi-Jung Kwon, Unknown
TITLE: A phase 1/2, open-label, multicenter, first-in-human study to evaluate the safety, pharmacokinetics, and anti-tumor activity of YH32367 in patients (pts) with HER2+ locally advanced/metastatic (a/m) solid tumors
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10444
ABSTRACT: Abstract is embargoed at this time.

09,

Abst_ID: CT071
SESSION: First-in-Human Phase I Clinical Trials 1
START: 4/28/2025 2:00:00 PM
END: 4/28/2025 5:00:00 PM
PRESENTER: Andrew Davis, MD
TITLE: Phase I trial of trastuzumab deruxtecan in combination with neratinib in solid tumors with HER2 alterations (NCI 10495)
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10447
ABSTRACT: Abstract is embargoed at this time.

10,

Abst_ID: CT075
SESSION: First-in-Human Phase I Clinical Trials 1
START: 4/28/2025 2:00:00 PM
END: 4/28/2025 5:00:00 PM
PRESENTER: Angelina Daisy Goodrich, PhD
TITLE: Phase 1a/1b dose-escalation study of efbalropendekin alfa (XmAb24306) as single-agent and with atezolizumab in solid tumors
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10451
ABSTRACT: Abstract is embargoed at this time.

11,

Abst_ID: CT077
SESSION: First-in-Human Phase I Clinical Trials 1
START: 4/28/2025 2:00:00 PM
END: 4/28/2025 5:00:00 PM
PRESENTER: Sherri Smith
TITLE: Pharmacodynamic characterization of PRS-344/S095012, a PD-L1x4-1BB antibody-Anticalin fusion protein (Mabcalin), in a dose escalation study in patients with advanced solid tumors
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10453
ABSTRACT: Abstract is embargoed at this time.

12,

Abst_ID: CT078
SESSION: First-in-Human Phase I Clinical Trials 1
START: 4/28/2025 2:00:00 PM
END: 4/28/2025 5:00:00 PM
PRESENTER: Emiliano Calvo, MD, PhD
TITLE: Results of a phase 1 first-in-human study of PRS-344/S095012, a PD-L1x4-1BB antibody-Anticalin fusion protein (Mabcalin), in patients with previously treated advanced solid tumors
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10454
ABSTRACT: Abstract is embargoed at this time.

13,

Abst_ID: CT079
SESSION: First-in-Human Phase I Clinical Trials 1
START: 4/28/2025 2:00:00 PM
END: 4/28/2025 5:00:00 PM
PRESENTER: Kimberly Macasevich
TITLE: Pharmacodynamic (PD) and exploratory biomarker (BM) analysis of the PRMT5 inhibitor BMS-986504 in patients (pts) with advanced solid tumors with homozygous MTAP deletion (MTAP-del)
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10455
ABSTRACT: Abstract is embargoed at this time.

14,

Abst_ID: CT084
SESSION: Phase II and Phase III Clinical Trials
START: 4/28/2025 2:00:00 PM
END: 4/28/2025 5:00:00 PM
PRESENTER: Jing Hao, PhD
TITLE: Prediction of surufatinib treatment outcome in advanced grade 3 neuroendocrine tumors (NET G3) patients
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10547
ABSTRACT: Abstract is embargoed at this time.

15,

Abst_ID: CT085
SESSION: Phase II and Phase III Clinical Trials
START: 4/28/2025 2:00:00 PM
END: 4/28/2025 5:00:00 PM
PRESENTER: Wangxia Lv
TITLE: A multi-cohort study of treatment regimens for metastatic colorectal cancer (mCRC): Subgroup analysis of sequential therapy between fruquintinib and regorafenib
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10548
ABSTRACT: Abstract is embargoed at this time.

16,

Abst_ID: CT110
SESSION: Phase I Clinical Trials in Progress 1
START: 4/28/2025 2:00:00 PM
END: 4/28/2025 5:00:00 PM
PRESENTER: Hcg Hcg
TITLE: An open-label, phase Ib dose-expansion study to assess the efficacy of CD137/FAP agonist BI 765179 plus pembrolizumab as a first-line treatment in metastatic or incurable, recurrent programmed cell death ligand-1 (PD-L1)-positive, head and neck squamous cell carcinoma (HNSCC)
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10571
ABSTRACT: Abstract is embargoed at this time.

17,

Abst_ID: CT113
SESSION: Phase I Clinical Trials in Progress 1
START: 4/28/2025 2:00:00 PM
END: 4/28/2025 5:00:00 PM
PRESENTER: Antoine Italiano, MD;PhD
TITLE: A first-in-human phase 1, multicenter, open-label study of M3554, a novel anti-GD2 antibody-drug conjugate (ADC), in patients with advanced solid tumors
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10574
ABSTRACT: Abstract is embargoed at this time.

18,

Abst_ID: CT116
SESSION: Phase I Clinical Trials in Progress 1
START: 4/28/2025 2:00:00 PM
END: 4/28/2025 5:00:00 PM
PRESENTER: Guidong Zhu, PhD
TITLE: A first-in-human phase 1 study on the safety, PK, receptor occupancy, and pharmacodynamic markers of SPX-303, a first-in-class LILRB2×PD-L1 bispecific antibody
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10577
ABSTRACT: Abstract is embargoed at this time.

19,

Abst_ID: CT117
SESSION: Phase I Clinical Trials in Progress 1
START: 4/28/2025 2:00:00 PM
END: 4/28/2025 5:00:00 PM
PRESENTER: Zev Wainberg, MD
TITLE: PROCEADE PanTumor: A Phase 1b/2, multicenter study of precemtabart tocentecan (M9140), an anti-CEACAM5 antibody-drug conjugate (ADC) with exatecan payload, in patients with advanced solid tumors
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10578
ABSTRACT: Abstract is embargoed at this time.

20,

Abst_ID: CT118
SESSION: Phase I Clinical Trials in Progress 1
START: 4/28/2025 2:00:00 PM
END: 4/28/2025 5:00:00 PM
PRESENTER: Minori Rosales, MD;PhD
TITLE: A phase 1 study of CTX-8371, a bispecific PD-1/PD-L1 antibody, in patients with advanced malignancies
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10579
ABSTRACT: Abstract is embargoed at this time.

21,

Abst_ID: CT121
SESSION: Phase I Clinical Trials in Progress 1
START: 4/28/2025 2:00:00 PM
END: 4/28/2025 5:00:00 PM
PRESENTER: Baoxia Zhang, BS
TITLE: A phase 1/2a, multicenter, open-label, first in human study of a bispecific ADC targeting B7H3 and PDL1 (DB-1419) in advanced or metastatic solid tumors
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10582
ABSTRACT: Abstract is embargoed at this time.

22,

Abst_ID: CT023
SESSION: Phase 0 and Phase I Clinical Trials
START: 4/28/2025 9:00:00 AM
END: 4/28/2025 12:00:00 PM
PRESENTER: Shwetal Mehta, PhD
TITLE: A phase 0/1 ‘trigger’ trial of BDTX-1535 in recurrent glioblastoma (GBM) patients with EGFR alterations or fusions
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10480
ABSTRACT: Abstract is embargoed at this time.

23,

Abst_ID: CT027
SESSION: Phase 0 and Phase I Clinical Trials
START: 4/28/2025 9:00:00 AM
END: 4/28/2025 12:00:00 PM
PRESENTER: Shenqi Wang, MD
TITLE: Imlunestrant, a novel orally bioavailable selective estrogen receptor degrader (SERD) in Chinese patients with ER positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer (mBC): Results from a phase 1 study
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10484
ABSTRACT: Abstract is embargoed at this time.

24,

Abst_ID: CT029
SESSION: Phase 0 and Phase I Clinical Trials
START: 4/28/2025 9:00:00 AM
END: 4/28/2025 12:00:00 PM
PRESENTER: Guiling Li, MD
TITLE: Preliminary outcomes from a phase 1b/2 study of the highly potent PI3K-mTOR dual inhibitor WX390 combined with toripalimab in patients with advanced cervical cancer
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10486
ABSTRACT: Abstract is embargoed at this time.

25,

Abst_ID: CT038
SESSION: Phase 0 and Phase I Clinical Trials
START: 4/28/2025 9:00:00 AM
END: 4/28/2025 12:00:00 PM
PRESENTER: Olivia Adams
TITLE: Phase 1 study of anti-CCR8 antibody CHS-114 with and without anti-PD-1 antibody toripalimab in patients with advanced solid tumors
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10495
ABSTRACT: Abstract is embargoed at this time.

26,

Abst_ID: CT039
SESSION: Phase 0 and Phase I Clinical Trials
START: 4/28/2025 9:00:00 AM
END: 4/28/2025 12:00:00 PM
PRESENTER: Jong Park, MD
TITLE: Results of a first-in-human phase 1 trial of anchored IL-12 drug conjugate (ANK-101)
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10496
ABSTRACT: Abstract is embargoed at this time.

27,

Abst_ID: CT041
SESSION: Phase 0 and Phase I Clinical Trials
START: 4/28/2025 9:00:00 AM
END: 4/28/2025 12:00:00 PM
PRESENTER: Thierry Guillaudeux, PhD
TITLE: Initial results from a first in human phase 1 study of KVA12123, an anti-VISTA antibody, alone and in combination with pembrolizumab in patients with advanced solid tumors
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10498
ABSTRACT: Abstract is embargoed at this time.

28,

Abst_ID: CT046
SESSION: Phase 0 and Phase I Clinical Trials
START: 4/28/2025 9:00:00 AM
END: 4/28/2025 12:00:00 PM
PRESENTER: Carlos Torrado Martin, MD
TITLE: Clinical and translational study of the TGF-β monoclonal antibody SAR439459 in combination with the PD-1 inhibitor cemiplimab for patients (pts) with advanced solid tumors: Results from the phase 1b TACTIC trial
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10503
ABSTRACT: Abstract is embargoed at this time.

26,

Abst_ID: CT204
SESSION: Biologics and T-cell Engagers
START: 4/29/2025 10:36:00 AM
END: 4/29/2025 10:51:00 AM
PRESENTER: Shanu Modi, MD
TITLE: Phase 1a/b study of runimotamab, a HER2 x CD3 T cell-engaging bispecific antibody, administered as a single agent and in combination with trastuzumab in patients with HER2-expressing breast cancer (BC)
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10428
ABSTRACT: Abstract is embargoed at this time.

27,

Abst_ID: CT233
SESSION: Phase II and Phase III Clinical Trials in Progress
START: 4/29/2025 2:00:00 PM
END: 4/29/2025 5:00:00 PM
PRESENTER: Denise D’Andrea, MD
TITLE: A phase 2b study of subcutaneous amivantamab with lazertinib as first-line treatment, or with chemotherapy as second-line treatment, for EGFR-mutated non-small cell lung cancer (NSCLC): COPERNICUS
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10602
ABSTRACT: Abstract is embargoed at this time.

28,

Abst_ID: CT262
SESSION: Innovative Approaches to Key Molecular Targets
START: 4/29/2025 2:35:00 PM
END: 4/29/2025 2:45:00 PM
PRESENTER: Alison Schram, MD
TITLE: Efficacy and safety of the combination PKMYT1-inhibitor lunresertib and ATR-inhibitor camonsertib in patients with ovarian and endometrial cancers: Phase I MYTHIC study (NCT04855656)
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10408
ABSTRACT: Abstract is embargoed at this time.

29,

Abst_ID: CT267
SESSION: Innovative Approaches to Key Molecular Targets
START: 4/29/2025 3:50:00 PM
END: 4/29/2025 4:00:00 PM
PRESENTER: Susanna Ulahannan, MD
TITLE: First results of ART0380 (an ATR kinase inhibitor) with low dose irinotecan in advanced or metastatic solid tumors
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10413
ABSTRACT: Abstract is embargoed at this time.

30,

Abst_ID: CT268
SESSION: Innovative Approaches to Key Molecular Targets
START: 4/29/2025 4:05:00 PM
END: 4/29/2025 4:15:00 PM
PRESENTER: Trupti Lingaraj
TITLE: Preliminary results from a first-in-human study of IK-595, an oral MEK/RAF molecular glue, in patients with RAS- or RAF-altered advanced solid tumors
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10414
ABSTRACT: Abstract is embargoed at this time.

31,

Abst_ID: CT135
SESSION: First-in-Human Phase I Clinical Trials 2
START: 4/29/2025 9:00:00 AM
END: 4/29/2025 12:00:00 PM
PRESENTER: Lu Lu, PhD
TITLE: Safety and efficacy of QLC1101 in KRAS G12D-mutant advanced solid tumors: results from a phase 1a study
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10456
ABSTRACT: Abstract is embargoed at this time.

32,

Abst_ID: CT136
SESSION: First-in-Human Phase I Clinical Trials 2
START: 4/29/2025 9:00:00 AM
END: 4/29/2025 12:00:00 PM
PRESENTER: Sunghwan Kim, PhD
TITLE: First-in-human studies of VRN110755 in NSCLC patients with EGFR mutations: Safety, pharmacokinetics, and early efficacy assessment
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10457
ABSTRACT: Abstract is embargoed at this time.

33,

Abst_ID: CT137
SESSION: First-in-Human Phase I Clinical Trials 2
START: 4/29/2025 9:00:00 AM
END: 4/29/2025 12:00:00 PM
PRESENTER: Prantesh Jain, MD
TITLE: Initial results from a phase 1 study of an A2a receptor antagonist, administered as monotherapy and in combination with anti-PD1 therapy in patients with advanced non-small cell lung cancer
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10458
ABSTRACT: Abstract is embargoed at this time.

34,

Abst_ID: CT142
SESSION: First-in-Human Phase I Clinical Trials 2
START: 4/29/2025 9:00:00 AM
END: 4/29/2025 12:00:00 PM
PRESENTER: Pumin Zhang, PhD
TITLE: The first-in-human trial of USP28 inhibitor CT1113
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10463
ABSTRACT: Abstract is embargoed at this time.

35,

Abst_ID: CT147
SESSION: First-in-Human Phase I Clinical Trials 2
START: 4/29/2025 9:00:00 AM
END: 4/29/2025 12:00:00 PM
PRESENTER: Andrew Garton
TITLE: Pharmacokinetics (PK) and pharmacodynamics (PD) of ISB 2001, a novel BCMAxCD38xCD3 trispecific antibody from the first-in-human (FIH) phase 1 study in relapsed/refractory multiple myeloma patients
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10468
ABSTRACT: Abstract is embargoed at this time.

36,

Abst_ID: CT152
SESSION: First-in-Human Phase I Clinical Trials 2
START: 4/29/2025 9:00:00 AM
END: 4/29/2025 12:00:00 PM
PRESENTER: Tongfu Xu, PhD
TITLE: A phase I study of POLQ inhibitor SYN818 as monotherapy in adult patients with locally advanced or metastatic solid tumors
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10473
ABSTRACT: Abstract is embargoed at this time.

37,

Abst_ID: CT153
SESSION: First-in-Human Phase I Clinical Trials 2
START: 4/29/2025 9:00:00 AM
END: 4/29/2025 12:00:00 PM
PRESENTER: Gerald Falchook, MD
TITLE: First in human phase 1 trial of the SRC family kinase inhibitor NXP900 in patients with advanced solid tumors
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10474
ABSTRACT: Abstract is embargoed at this time.

38,

Abst_ID: CT154
SESSION: First-in-Human Phase I Clinical Trials 2
START: 4/29/2025 9:00:00 AM
END: 4/29/2025 12:00:00 PM
PRESENTER: Samara Violet
TITLE: BDC-3042, a first-in-class Dectin-2 agonist, in patients with advanced malignancies: Results from the first-in-human dose-escalation study
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10475
ABSTRACT: Abstract is embargoed at this time.

39,

Abst_ID: CT156
SESSION: First-in-Human Phase I Clinical Trials 2
START: 4/29/2025 9:00:00 AM
END: 4/29/2025 12:00:00 PM
PRESENTER: Suad Obeid
TITLE: Phase 1 dose-optimization study evaluating the safety of ginisortamab (UCB6114), an anti-gremlin-1 monoclonal antibody (mAb) with first-in-class potential, as monotherapy in advanced solid tumors
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10477
ABSTRACT: Abstract is embargoed at this time.

40,

Abst_ID: CT157
SESSION: First-in-Human Phase I Clinical Trials 2
START: 4/29/2025 9:00:00 AM
END: 4/29/2025 12:00:00 PM
PRESENTER: Angelina Daisy Goodrich, PhD
TITLE: Phase 1 dose-escalation study of linclatamig, a LY6G6D×CD3 T cell-engaging bispecific antibody, in patients with colorectal cancer
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10478
ABSTRACT: Abstract is embargoed at this time.

41,

Abst_ID: CT161
SESSION: Phase II Clinical Trials 1
START: 4/29/2025 9:00:00 AM
END: 4/29/2025 12:00:00 PM
PRESENTER: Anthony El-Khoueiry, MD
TITLE: Dose-optimization using exposure response analysis in AFM24 (in monotherapy and with atezolizumab) in patients with advanced/metastatic non-small cell lung cancer
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10506
ABSTRACT: Abstract is embargoed at this time.

42,

Abst_ID: CT168
SESSION: Phase II Clinical Trials 1
START: 4/29/2025 9:00:00 AM
END: 4/29/2025 12:00:00 PM
PRESENTER: Christine Parseghian, MD
TITLE: EMB-01, an EGFR/cMET bispecific antibody, in metastatic colorectal cancer: Results from an international phase Ib/II study
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10513
ABSTRACT: Abstract is embargoed at this time.

43,

Abst_ID: CT169
SESSION: Phase II Clinical Trials 1
START: 4/29/2025 9:00:00 AM
END: 4/29/2025 12:00:00 PM
PRESENTER: James Cleary, MD;PhD
TITLE: Phase Ib/II open-label, randomized study of atezolizumab + regorafenib + AB928 or atezolizumab + regorafenib vs regorafenib for patients with microsatellite-stable, refractory metastatic colorectal cancer in MORPHEUS-CRC
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10514
ABSTRACT: Abstract is embargoed at this time.

44,

Abst_ID: CT172
SESSION: Phase II Clinical Trials 1
START: 4/29/2025 9:00:00 AM
END: 4/29/2025 12:00:00 PM
PRESENTER: Yinchao Zhang, BS
TITLE: Updated efficacy and safety data for cadonilimab plus regorafenib as second-line or later therapy in advanced hepatocellular carcinoma (aHCC)
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10517
ABSTRACT: Abstract is embargoed at this time.

45,

Abst_ID: CT184
SESSION: Phase I Clinical Trials in Progress 2
START: 4/29/2025 9:00:00 AM
END: 4/29/2025 12:00:00 PM
PRESENTER: Sun Min Lim, MD;PhD
TITLE: Phase 1/2 clinical trial of JIN-A02, a 4th generation EGFR-TKI in EGFR mutated advanced/metastatic non-small cell lung cancer
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10584
ABSTRACT: Abstract is embargoed at this time.

46,

Abst_ID: CT185
SESSION: Phase I Clinical Trials in Progress 2
START: 4/29/2025 9:00:00 AM
END: 4/29/2025 12:00:00 PM
PRESENTER: Mark Chiu, PhD
TITLE: Trispecific EGFR x cMET x VEGF antibody, TAVO412, has clinical responses in esophageal and lung cancers
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10585
ABSTRACT: Abstract is embargoed at this time.

47,

Abst_ID: CT188
SESSION: Phase I Clinical Trials in Progress 2
START: 4/29/2025 9:00:00 AM
END: 4/29/2025 12:00:00 PM
PRESENTER: William McKean, MD, PhD
TITLE: BEHOLD-1: A Phase 1 Dose Escalation Study of GSK5733584, a B7-H4-Targeted Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors, Including Dose Expansion in Patients With Endometrial and Platinum-Resistant Ovarian Cancer
URL: https://www.abstractsonline.com/pp8/#!/20273/presentation/10588
ABSTRACT: Abstract is embargoed at this time.